Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

H. West; M. McCleod; M. Hussein; A. Morabito; A. Rittmeyer; H.J. Conter; H.-G. Kopp; D. Daniel; S. McCune; T. Mekhail; A. Zer; N. Reinmuth; A. Sadiq; A. Sandler; W. Lin; T. Ochi Lohmann; V. Archer; L. Wang; M. Kowanetz; F. Cappuzzo

doi:10.1016/S1470-2045(19)30167-6

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

H. West, M. McCleod, M. Hussein, A. Morabito, A. Rittmeyer, H.J. Conter, H.-G. Kopp, D. Daniel, S. McCune, T. Mekhail, A. Zer, N. Reinmuth, A. Sadiq, A. Sandler, W. Lin, T. Ochi Lohmann, V. Archer, L. Wang, M. Kowanetz, F. Cappuzzo

Centro di Riferimento Oncologico

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	924-937
Number of pages	14
Journal	The Lancet Oncology
Volume	20
Issue number	7
DOIs	https://doi.org/10.1016/S1470-2045(19)30167-6
Publication status	Published - 2019

Access to Document

10.1016/S1470-2045(19)30167-6

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068055361&doi=10.1016%2fS1470-2045%2819%2930167-6&partnerID=40&md5=bd243a14b452b7f8cccf396383c9c7ae

Cite this

West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H-G., Daniel, D., McCune, S., Mekhail, T., Zer, A., Reinmuth, N., Sadiq, A., Sandler, A., Lin, W., Ochi Lohmann, T., Archer, V., Wang, L., Kowanetz, M., & Cappuzzo, F. (2019). Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology, 20(7), 924-937. https://doi.org/10.1016/S1470-2045(19)30167-6

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. / West, H.; McCleod, M.; Hussein, M.; Morabito, A.; Rittmeyer, A.; Conter, H.J.; Kopp, H.-G.; Daniel, D.; McCune, S.; Mekhail, T.; Zer, A.; Reinmuth, N.; Sadiq, A.; Sandler, A.; Lin, W.; Ochi Lohmann, T.; Archer, V.; Wang, L.; Kowanetz, M.; Cappuzzo, F.

In: The Lancet Oncology, Vol. 20, No. 7, 2019, p. 924-937.

Research output: Contribution to journal › Article › peer-review

West, H, McCleod, M, Hussein, M, Morabito, A, Rittmeyer, A, Conter, HJ, Kopp, H-G, Daniel, D, McCune, S, Mekhail, T, Zer, A, Reinmuth, N, Sadiq, A, Sandler, A, Lin, W, Ochi Lohmann, T, Archer, V, Wang, L, Kowanetz, M & Cappuzzo, F 2019, 'Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial', The Lancet Oncology, vol. 20, no. 7, pp. 924-937. https://doi.org/10.1016/S1470-2045(19)30167-6

West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 2019;20(7):924-937. https://doi.org/10.1016/S1470-2045(19)30167-6

West, H. ; McCleod, M. ; Hussein, M. ; Morabito, A. ; Rittmeyer, A. ; Conter, H.J. ; Kopp, H.-G. ; Daniel, D. ; McCune, S. ; Mekhail, T. ; Zer, A. ; Reinmuth, N. ; Sadiq, A. ; Sandler, A. ; Lin, W. ; Ochi Lohmann, T. ; Archer, V. ; Wang, L. ; Kowanetz, M. ; Cappuzzo, F. / Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. In: The Lancet Oncology. 2019 ; Vol. 20, No. 7. pp. 924-937.

@article{4619eb3ea16e4ec4a766102b48b93a39,

title = "Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial",

author = "H. West and M. McCleod and M. Hussein and A. Morabito and A. Rittmeyer and H.J. Conter and H.-G. Kopp and D. Daniel and S. McCune and T. Mekhail and A. Zer and N. Reinmuth and A. Sadiq and A. Sandler and W. Lin and {Ochi Lohmann}, T. and V. Archer and L. Wang and M. Kowanetz and F. Cappuzzo",

note = "Cited By :1 Export Date: 10 July 2019",

year = "2019",

doi = "10.1016/S1470-2045(19)30167-6",

language = "English",

volume = "20",

pages = "924--937",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "7",

}

TY - JOUR

T1 - Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

AU - West, H.

AU - McCleod, M.

AU - Hussein, M.

AU - Morabito, A.

AU - Rittmeyer, A.

AU - Conter, H.J.

AU - Kopp, H.-G.

AU - Daniel, D.

AU - McCune, S.

AU - Mekhail, T.

AU - Zer, A.

AU - Reinmuth, N.

AU - Sadiq, A.

AU - Sandler, A.

AU - Lin, W.

AU - Ochi Lohmann, T.

AU - Archer, V.

AU - Wang, L.

AU - Kowanetz, M.

AU - Cappuzzo, F.

N1 - Cited By :1 Export Date: 10 July 2019

PY - 2019

Y1 - 2019

U2 - 10.1016/S1470-2045(19)30167-6

DO - 10.1016/S1470-2045(19)30167-6

M3 - Article

VL - 20

SP - 924

EP - 937

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 7

ER -